FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and robust revenue growth.

The company reported revenue of RMB3.53 billion for 2025, representing a 30.2% year-on-year increase, and achieved a net profit of approximately RMB12 million, marking a recovery from a net loss in the previous year. This performance exceeded market expectations and was driven by growth across its online retail pharmacy, wholesale, and comprehensive medical services segments.

Fangzhou's AI-driven chronic disease management strategy appears to be gaining traction, with the company reporting a 35% increase in average monthly active users to 13.7 million. The launch of its "XingShi" large language model and strategic partnerships with pharmaceutical companies like Novo Nordisk and Innovent Biologics have strengthened its position in the growing AI-enabled healthcare market in China.